Skip to main content

Table 3 PROGRESS intensive care treatment

From: The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes

Variable DrotAA
n = 882
Non-DrotAA
n = 11,610
Total
n = 12,492
P value
IV fluid resuscitation, n (%) (n = 782)
718 (91.8)
(n = 10,492)
9053 (86.3)
(n = 11,274)
9771 (86.7)
<0.001
Mechanical ventilation, n (%) (n = 882)
842 (95.5)
(n = 11,609)
9838 (84.7)
(n = 12,491)
10,680 (85.5)
<0.001
Vasopressors, n (%) (n = 882)
828 (93.9)
(n = 11,608)
9005 (77.6)
(n = 12,490)
9833 (78.7)
<0.001
Nutrition:     
   Enteral, n (%) (n = 882)
678 (76.9)
(n = 11,588)
8369 (72.2)
(n = 12,470)
9047 (72.6)
0.003
   Parenteral, n (%) (n = 882)
383 (43.4)
(n = 11,601)
3726 (32.1)
(n = 12,483)
4109 (32.9)
<0.001
Heparin:     
   Low molecular weight (n = 871)
418 (48.0)
(n = 11,586)
3879 (33.5)
(n = 12,457)
4297 (34.5)
<0.001
   Unfractionated (n = 868)
345 (39.8)
(n = 11,601)
4628 (39.9)
(n = 12,469)
4973 (39.9)
0.932
Steroids:     
   Low dose (n = 878)
499 (56.8)
(n = 11,559)
3994 (34.6)
(n = 12,437)
4493 (36.1)
<0.001
   High dose (n = 880)
156 (17.7)
(n = 11,600)
1397 (12.0)
(n = 12,480)
1553 (12.4)
<0.001
Mechanical VTE prophylaxis (n = 765)
295 (38.6)
(n = 10,371)
2407 (23.2)
(n = 11,136)
2702 (24.3)
<0.001
Renal replacement therapy (n = 876)
283 (32.3)
(n = 11,598)
2383 (20.6)
(n = 12,474)
2666 (21.4)
<0.001
Platelet transfusion (n = 780)
178 (22.8)
(n = 10,483)
1677 (16.0)
(n = 11,263)
1855 (16.5)
<0.001
  1. DrotAA = drotrecogin alfa (activated); PROGRESS = Promoting Global Research Excellence in Severe Sepsis; VTE = venous thromboembolism.